Department of Allergy and Clinical Immunology, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, Guangzhou 510120, P.R. China; Guangzhou National Laboratory, Guangzhou, Guangdong 510005, P.R. China.
Department of Allergy and Clinical Immunology, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, Guangzhou 510120, P.R. China; Guangzhou National Laboratory, Guangzhou, Guangdong 510005, P.R. China.
Cell Rep Med. 2024 Nov 19;5(11):101821. doi: 10.1016/j.xcrm.2024.101821.
Stem and progenitor cell-based regenerative therapies have the potential to cure chronic respiratory diseases. Yan et al. reported a clinical trial of autologous P63 progenitor cell transplantation in bronchiectasis patients, highlighting autologous transplantation of P63 progenitor cells as a novel candidate therapeutic option to improve pulmonary gas exchange function and quality of life.
基于干细胞和祖细胞的再生疗法有可能治愈慢性呼吸系统疾病。Yan 等人报告了一项关于支气管扩张症患者自体 P63 祖细胞移植的临床试验，强调了自体 P63 祖细胞移植作为改善肺气体交换功能和生活质量的一种新的候选治疗选择。
